OptimizeRx Corp. (NASDAQ: OPRX) Stock Competitors & Peer Comparison

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while GEHCV trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas GEHCV's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, OPRX is less volatile compared to GEHCV. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check GEHCV's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, BTSG has a market cap of 11.6B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while BTSG trades at $59.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas BTSG's P/E ratio is 47.69. In terms of profitability, OPRX's ROE is +0.04%, compared to BTSG's ROE of +0.15%. Regarding short-term risk, OPRX is more volatile compared to BTSG. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check BTSG's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, BTSGU has a market cap of 11.5B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while BTSGU trades at $195.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas BTSGU's P/E ratio is 176.79. In terms of profitability, OPRX's ROE is +0.04%, compared to BTSGU's ROE of +0.15%. Regarding short-term risk, OPRX is more volatile compared to BTSGU. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check BTSGU's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, TEM has a market cap of 11.2B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while TEM trades at $64.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas TEM's P/E ratio is -128.08. In terms of profitability, OPRX's ROE is +0.04%, compared to TEM's ROE of -0.55%. Regarding short-term risk, OPRX is less volatile compared to TEM. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check TEM's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while SGFY trades at $30.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas SGFY's P/E ratio is 70.91. In terms of profitability, OPRX's ROE is +0.04%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, OPRX is more volatile compared to SGFY. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check SGFY's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, HQY has a market cap of 8.1B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while HQY trades at $96.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas HQY's P/E ratio is 22.52. In terms of profitability, OPRX's ROE is +0.04%, compared to HQY's ROE of +0.11%. Regarding short-term risk, OPRX is more volatile compared to HQY. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check HQY's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, TXG has a market cap of 7.8B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while TXG trades at $61.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas TXG's P/E ratio is -104.31. In terms of profitability, OPRX's ROE is +0.04%, compared to TXG's ROE of -0.09%. Regarding short-term risk, OPRX is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check TXG's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, HNGE has a market cap of 6.8B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while HNGE trades at $87.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas HNGE's P/E ratio is 46.70. In terms of profitability, OPRX's ROE is +0.04%, compared to HNGE's ROE of +0.30%. Regarding short-term risk, OPRX is more volatile compared to HNGE. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check HNGE's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while RCM trades at $14.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas RCM's P/E ratio is -102.21. In terms of profitability, OPRX's ROE is +0.04%, compared to RCM's ROE of +0.00%. Regarding short-term risk, OPRX is more volatile compared to RCM. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check RCM's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, WAY has a market cap of 5B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while WAY trades at $26.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas WAY's P/E ratio is 17.38. In terms of profitability, OPRX's ROE is +0.04%, compared to WAY's ROE of +0.04%. Regarding short-term risk, OPRX is more volatile compared to WAY. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check WAY's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, DOCS has a market cap of 5B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while DOCS trades at $26.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas DOCS's P/E ratio is 17.47. In terms of profitability, OPRX's ROE is +0.04%, compared to DOCS's ROE of +0.17%. Regarding short-term risk, OPRX is more volatile compared to DOCS. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check DOCS's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, HTFL has a market cap of 4.1B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while HTFL trades at $47.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas HTFL's P/E ratio is -23.77. In terms of profitability, OPRX's ROE is +0.04%, compared to HTFL's ROE of -0.42%. Regarding short-term risk, OPRX is more volatile compared to HTFL. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check HTFL's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while ONEM trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas ONEM's P/E ratio is -7.77. In terms of profitability, OPRX's ROE is +0.04%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, OPRX is more volatile compared to ONEM. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check ONEM's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, PRVA has a market cap of 2.6B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while PRVA trades at $20.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas PRVA's P/E ratio is 99.00. In terms of profitability, OPRX's ROE is +0.04%, compared to PRVA's ROE of +0.00%. Regarding short-term risk, OPRX is more volatile compared to PRVA. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check PRVA's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while NXGN trades at $23.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas NXGN's P/E ratio is -266.00. In terms of profitability, OPRX's ROE is +0.04%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, OPRX is more volatile compared to NXGN. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check NXGN's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, OMCL has a market cap of 1.5B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while OMCL trades at $33.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas OMCL's P/E ratio is 17.32. In terms of profitability, OPRX's ROE is +0.04%, compared to OMCL's ROE of +0.03%. Regarding short-term risk, OPRX is more volatile compared to OMCL. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check OMCL's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, OMDA has a market cap of 1.4B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while OMDA trades at $23.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas OMDA's P/E ratio is 338.43. In terms of profitability, OPRX's ROE is +0.04%, compared to OMDA's ROE of +0.02%. Regarding short-term risk, OPRX is more volatile compared to OMDA. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check OMDA's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while AGTI trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas AGTI's P/E ratio is -71.79. In terms of profitability, OPRX's ROE is +0.04%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, OPRX is more volatile compared to AGTI. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check AGTI's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, CERT has a market cap of 1.3B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while CERT trades at $8.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas CERT's P/E ratio is 20.87. In terms of profitability, OPRX's ROE is +0.04%, compared to CERT's ROE of -0.07%. Regarding short-term risk, OPRX is more volatile compared to CERT. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check CERT's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, GDRX has a market cap of 1.2B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while GDRX trades at $3.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas GDRX's P/E ratio is 11.03. In terms of profitability, OPRX's ROE is +0.04%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, OPRX is more volatile compared to GDRX. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check GDRX's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, TDOC has a market cap of 1.2B. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while TDOC trades at $6.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas TDOC's P/E ratio is -6.57. In terms of profitability, OPRX's ROE is +0.04%, compared to TDOC's ROE of -0.13%. Regarding short-term risk, OPRX is more volatile compared to TDOC. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check TDOC's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, HSTM has a market cap of 858.3M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while HSTM trades at $29.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas HSTM's P/E ratio is 40.81. In terms of profitability, OPRX's ROE is +0.04%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, OPRX is more volatile compared to HSTM. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check HSTM's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while CCLDO trades at $27.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas CCLDO's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, OPRX is more volatile compared to CCLDO. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check CCLDO's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, PHR has a market cap of 750.4M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while PHR trades at $12.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas PHR's P/E ratio is 43.36. In terms of profitability, OPRX's ROE is +0.04%, compared to PHR's ROE of +0.03%. Regarding short-term risk, OPRX is more volatile compared to PHR. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check PHR's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, SOPH has a market cap of 682.9M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while SOPH trades at $8.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas SOPH's P/E ratio is -7.33. In terms of profitability, OPRX's ROE is +0.04%, compared to SOPH's ROE of -1.37%. Regarding short-term risk, OPRX is less volatile compared to SOPH. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check SOPH's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, CTEV has a market cap of 669.3M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while CTEV trades at $39.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas CTEV's P/E ratio is -2.31. In terms of profitability, OPRX's ROE is +0.04%, compared to CTEV's ROE of +1.40%. Regarding short-term risk, OPRX is more volatile compared to CTEV. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check CTEV's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while MPLN-WT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to MPLN-WT's ROE of +1.40%. Regarding short-term risk, OPRX is less volatile compared to MPLN-WT. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check MPLN-WT's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while ACCD trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas ACCD's P/E ratio is -3.08. In terms of profitability, OPRX's ROE is +0.04%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, OPRX is more volatile compared to ACCD. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check ACCD's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while SHCR trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas SHCR's P/E ratio is -3.76. In terms of profitability, OPRX's ROE is +0.04%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, OPRX is more volatile compared to SHCR. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check SHCR's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, EVH has a market cap of 518M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while EVH trades at $4.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas EVH's P/E ratio is 35.42. In terms of profitability, OPRX's ROE is +0.04%, compared to EVH's ROE of -0.99%. Regarding short-term risk, OPRX is less volatile compared to EVH. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check EVH's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, NRC has a market cap of 492.4M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while NRC trades at $21.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas NRC's P/E ratio is 26.65. In terms of profitability, OPRX's ROE is +0.04%, compared to NRC's ROE of +0.48%. Regarding short-term risk, OPRX is more volatile compared to NRC. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check NRC's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while SLGC trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas SLGC's P/E ratio is -3.04. In terms of profitability, OPRX's ROE is +0.04%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, OPRX is less volatile compared to SLGC. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check SLGC's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while SLGCW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, OPRX's ROE is +0.04%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, OPRX is less volatile compared to SLGCW. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check SLGCW's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, TBRG has a market cap of 393.6M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while TBRG trades at $26.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas TBRG's P/E ratio is 9.37. In terms of profitability, OPRX's ROE is +0.04%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, OPRX is more volatile compared to TBRG. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check TBRG's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while MPLN trades at $23.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas MPLN's P/E ratio is -0.23. In terms of profitability, OPRX's ROE is +0.04%, compared to MPLN's ROE of +1.40%. Regarding short-term risk, OPRX is less volatile compared to MPLN. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check MPLN's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, SY has a market cap of 314.9M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while SY trades at $2.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas SY's P/E ratio is -7.27. In terms of profitability, OPRX's ROE is +0.04%, compared to SY's ROE of -0.16%. Regarding short-term risk, OPRX is more volatile compared to SY. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check SY's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while TRHC trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas TRHC's P/E ratio is -4.27. In terms of profitability, OPRX's ROE is +0.04%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, OPRX is more volatile compared to TRHC. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check TRHC's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while SMFR trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas SMFR's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to SMFR's ROE of -0.39%. Regarding short-term risk, OPRX is less volatile compared to SMFR. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check SMFR's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, SPOK has a market cap of 222.4M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while SPOK trades at $10.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas SPOK's P/E ratio is 17.75. In terms of profitability, OPRX's ROE is +0.04%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, OPRX is more volatile compared to SPOK. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check SPOK's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, AMWL has a market cap of 202.2M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while AMWL trades at $11.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas AMWL's P/E ratio is -2.69. In terms of profitability, OPRX's ROE is +0.04%, compared to AMWL's ROE of -0.33%. Regarding short-term risk, OPRX is more volatile compared to AMWL. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check AMWL's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, LFMDP has a market cap of 156.9M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while LFMDP trades at $23.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas LFMDP's P/E ratio is -709.24. In terms of profitability, OPRX's ROE is +0.04%, compared to LFMDP's ROE of -1.79%. Regarding short-term risk, OPRX is more volatile compared to LFMDP. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check LFMDP's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, LFMD has a market cap of 151.9M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while LFMD trades at $3.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas LFMD's P/E ratio is -6.28. In terms of profitability, OPRX's ROE is +0.04%, compared to LFMD's ROE of -1.79%. Regarding short-term risk, OPRX is more volatile compared to LFMD. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check LFMD's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while CPSI trades at $9.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas CPSI's P/E ratio is -183.80. In terms of profitability, OPRX's ROE is +0.04%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, OPRX is less volatile compared to CPSI. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check CPSI's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, HCAT has a market cap of 117.5M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while HCAT trades at $1.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas HCAT's P/E ratio is 7.95. In terms of profitability, OPRX's ROE is +0.04%, compared to HCAT's ROE of -1.30%. Regarding short-term risk, OPRX is more volatile compared to HCAT. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check HCAT's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while AUGX trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas AUGX's P/E ratio is -4.99. In terms of profitability, OPRX's ROE is +0.04%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, OPRX is more volatile compared to AUGX. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check AUGX's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, CCLD has a market cap of 105.8M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while CCLD trades at $2.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas CCLD's P/E ratio is 9.58. In terms of profitability, OPRX's ROE is +0.04%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, OPRX is less volatile compared to CCLD. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check CCLD's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, WORX has a market cap of 88M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while WORX trades at $5.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas WORX's P/E ratio is -6.40. In terms of profitability, OPRX's ROE is +0.04%, compared to WORX's ROE of -0.35%. Regarding short-term risk, OPRX is less volatile compared to WORX. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check WORX's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, DH has a market cap of 84.7M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while DH trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas DH's P/E ratio is 3.09. In terms of profitability, OPRX's ROE is +0.04%, compared to DH's ROE of -0.79%. Regarding short-term risk, OPRX is less volatile compared to DH. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check DH's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while FORA trades at $2.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas FORA's P/E ratio is -24.11. In terms of profitability, OPRX's ROE is +0.04%, compared to FORA's ROE of -0.17%. Regarding short-term risk, OPRX is more volatile compared to FORA. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check FORA's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while CCLDP trades at $19.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas CCLDP's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, OPRX is more volatile compared to CCLDP. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check CCLDP's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while SNCE trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas SNCE's P/E ratio is -0.27. In terms of profitability, OPRX's ROE is +0.04%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, OPRX is more volatile compared to SNCE. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check SNCE's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while AKLI trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas AKLI's P/E ratio is -0.71. In terms of profitability, OPRX's ROE is +0.04%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, OPRX is more volatile compared to AKLI. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check AKLI's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while SHLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas SHLT's P/E ratio is -3.87. In terms of profitability, OPRX's ROE is +0.04%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, OPRX is more volatile compared to SHLT. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check SHLT's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, ONMD has a market cap of 33M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while ONMD trades at $0.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas ONMD's P/E ratio is -3.62. In terms of profitability, OPRX's ROE is +0.04%, compared to ONMD's ROE of +2.35%. Regarding short-term risk, OPRX is more volatile compared to ONMD. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check ONMD's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while SHCRW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, OPRX's ROE is +0.04%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, OPRX is more volatile compared to SHCRW. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check SHCRW's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, ONMDW has a market cap of 31.1M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while ONMDW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas ONMDW's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to ONMDW's ROE of +2.35%. Regarding short-term risk, OPRX is less volatile compared to ONMDW. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check ONMDW's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while STRM trades at $5.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas STRM's P/E ratio is -2.40. In terms of profitability, OPRX's ROE is +0.04%, compared to STRM's ROE of -0.65%. Regarding short-term risk, OPRX is more volatile compared to STRM. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check STRM's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while RNLX trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas RNLX's P/E ratio is -0.33. In terms of profitability, OPRX's ROE is +0.04%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, OPRX is less volatile compared to RNLX. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check RNLX's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while LIFW trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas LIFW's P/E ratio is -0.02. In terms of profitability, OPRX's ROE is +0.04%, compared to LIFW's ROE of +1.56%. Regarding short-term risk, OPRX is more volatile compared to LIFW. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check LIFW's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while BBLN trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas BBLN's P/E ratio is -0.04. In terms of profitability, OPRX's ROE is +0.04%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, OPRX is less volatile compared to BBLN. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check BBLN's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, BFRG has a market cap of 10.1M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while BFRG trades at $0.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas BFRG's P/E ratio is -1.18. In terms of profitability, OPRX's ROE is +0.04%, compared to BFRG's ROE of -1.50%. Regarding short-term risk, OPRX is more volatile compared to BFRG. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check BFRG's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while ETAO trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas ETAO's P/E ratio is -0.01. In terms of profitability, OPRX's ROE is +0.04%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, OPRX is less volatile compared to ETAO. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check ETAO's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, MGRX has a market cap of 6.8M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while MGRX trades at $0.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas MGRX's P/E ratio is -0.30. In terms of profitability, OPRX's ROE is +0.04%, compared to MGRX's ROE of -1.06%. Regarding short-term risk, OPRX is less volatile compared to MGRX. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check MGRX's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while UPH-WT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, OPRX is less volatile compared to UPH-WT. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check UPH-WT's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while UPH trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas UPH's P/E ratio is -0.07. In terms of profitability, OPRX's ROE is +0.04%, compared to UPH's ROE of -1.05%. Regarding short-term risk, OPRX is less volatile compared to UPH. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check UPH's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while PEARW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas PEARW's P/E ratio is -0.00. In terms of profitability, OPRX's ROE is +0.04%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, OPRX is less volatile compared to PEARW. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check PEARW's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while PEAR trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas PEAR's P/E ratio is -0.08. In terms of profitability, OPRX's ROE is +0.04%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, OPRX is less volatile compared to PEAR. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check PEAR's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while OTRK trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas OTRK's P/E ratio is -0.02. In terms of profitability, OPRX's ROE is +0.04%, compared to OTRK's ROE of -2.11%. Regarding short-term risk, OPRX is more volatile compared to OTRK. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check OTRK's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while CMAX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas CMAX's P/E ratio is -0.00. In terms of profitability, OPRX's ROE is +0.04%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, OPRX is more volatile compared to CMAX. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check CMAX's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, BFRGW has a market cap of 1.4M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while BFRGW trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas BFRGW's P/E ratio is -0.92. In terms of profitability, OPRX's ROE is +0.04%, compared to BFRGW's ROE of -1.50%. Regarding short-term risk, OPRX is more volatile compared to BFRGW. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check BFRGW's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, ACON has a market cap of 1.3M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while ACON trades at $2.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas ACON's P/E ratio is -0.27. In terms of profitability, OPRX's ROE is +0.04%, compared to ACON's ROE of -0.59%. Regarding short-term risk, OPRX is less volatile compared to ACON. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check ACON's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while LIFWZ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to LIFWZ's ROE of +1.56%. Regarding short-term risk, OPRX is more volatile compared to LIFWZ. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check LIFWZ's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, HCTI has a market cap of 975.4K. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while HCTI trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas HCTI's P/E ratio is -0.11. In terms of profitability, OPRX's ROE is +0.04%, compared to HCTI's ROE of -0.56%. Regarding short-term risk, OPRX is less volatile compared to HCTI. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check HCTI's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, VSEEW has a market cap of 560.3K. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while VSEEW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas VSEEW's P/E ratio is -0.04. In terms of profitability, OPRX's ROE is +0.04%, compared to VSEEW's ROE of -4.01%. Regarding short-term risk, OPRX is less volatile compared to VSEEW. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check VSEEW's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while MSPRZ trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to MSPRZ's ROE of +1.56%. Regarding short-term risk, OPRX is less volatile compared to MSPRZ. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check MSPRZ's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, VSEE has a market cap of 245.6K. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while VSEE trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas VSEE's P/E ratio is -0.03. In terms of profitability, OPRX's ROE is +0.04%, compared to VSEE's ROE of -4.01%. Regarding short-term risk, OPRX is less volatile compared to VSEE. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check VSEE's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while KERN trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas KERN's P/E ratio is -0.01. In terms of profitability, OPRX's ROE is +0.04%, compared to KERN's ROE of -0.20%. Regarding short-term risk, OPRX is less volatile compared to KERN. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check KERN's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while KERNW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas KERNW's P/E ratio is -0.00. In terms of profitability, OPRX's ROE is +0.04%, compared to KERNW's ROE of -0.20%. Regarding short-term risk, OPRX is less volatile compared to KERNW. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check KERNW's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while LIFWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas LIFWW's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to LIFWW's ROE of +1.56%. Regarding short-term risk, OPRX is more volatile compared to LIFWW. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check LIFWW's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while CMAXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas CMAXW's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, OPRX is more volatile compared to CMAXW. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check CMAXW's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, ZCMD has a market cap of 32.1K. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while ZCMD trades at $0.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas ZCMD's P/E ratio is -0.03. In terms of profitability, OPRX's ROE is +0.04%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, OPRX is less volatile compared to ZCMD. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check ZCMD's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, ACONW has a market cap of 13.6K. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while ACONW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas ACONW's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to ACONW's ROE of -0.59%. Regarding short-term risk, OPRX is more volatile compared to ACONW. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check ACONW's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, CHNG has a market cap of 0. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while CHNG trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas CHNG's P/E ratio is -152.72. In terms of profitability, OPRX's ROE is +0.04%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, OPRX is more volatile compared to CHNG. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check CHNG's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, NH has a market cap of 0. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while NH trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas NH's P/E ratio is -0.12. In terms of profitability, OPRX's ROE is +0.04%, compared to NH's ROE of +0.35%. Regarding short-term risk, OPRX is less volatile compared to NH. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check NH's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, KURIU has a market cap of 0. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while KURIU trades at $9.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas KURIU's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to KURIU's ROE of +1.06%. Regarding short-term risk, OPRX is less volatile compared to KURIU. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check KURIU's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, MTBC has a market cap of 0. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while MTBC trades at $3.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas MTBC's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to MTBC's ROE of +0.19%. Regarding short-term risk, OPRX is less volatile compared to MTBC. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check MTBC's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, IMS has a market cap of 0. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while IMS trades at $31.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas IMS's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to IMS's ROE of +0.27%. Regarding short-term risk, OPRX is more volatile compared to IMS. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check IMS's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, AFFX has a market cap of 0. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while AFFX trades at $14.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas AFFX's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to AFFX's ROE of +0.03%. Regarding short-term risk, OPRX is more volatile compared to AFFX. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check AFFX's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, CSLT has a market cap of 0. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while CSLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas CSLT's P/E ratio is -37.27. In terms of profitability, OPRX's ROE is +0.04%, compared to CSLT's ROE of -0.42%. Regarding short-term risk, OPRX is more volatile compared to CSLT. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check CSLT's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, SMFRW has a market cap of 0. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while SMFRW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas SMFRW's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to SMFRW's ROE of -0.39%. Regarding short-term risk, OPRX is less volatile compared to SMFRW. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check SMFRW's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, MSPRV has a market cap of 0. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while MSPRV trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas MSPRV's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to MSPRV's ROE of N/A. Regarding short-term risk, OPRX is less volatile compared to MSPRV. This indicates lower risk in terms of short-term price fluctuations for OPRX.Check MSPRV's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, NAVA has a market cap of 0. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while NAVA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas NAVA's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to NAVA's ROE of +0.15%. Regarding short-term risk, OPRX is not fully comparable compared to NAVA. This indicates unavailable risk data in terms of short-term price fluctuations for OPRX.Check NAVA's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, CHNGU has a market cap of 0. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while CHNGU trades at $73.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas CHNGU's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, OPRX is more volatile compared to CHNGU. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check CHNGU's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, CNVY has a market cap of 0. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while CNVY trades at $10.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas CNVY's P/E ratio is -71.50. In terms of profitability, OPRX's ROE is +0.04%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, OPRX is more volatile compared to CNVY. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check CNVY's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, MTBCP has a market cap of 0. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while MTBCP trades at $26.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas MTBCP's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to MTBCP's ROE of +0.17%. Regarding short-term risk, OPRX is more volatile compared to MTBCP. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check MTBCP's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, MTBCO has a market cap of 0. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while MTBCO trades at $25.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas MTBCO's P/E ratio is N/A. In terms of profitability, OPRX's ROE is +0.04%, compared to MTBCO's ROE of +0.17%. Regarding short-term risk, OPRX is more volatile compared to MTBCO. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check MTBCO's competition here

OptimizeRx Corp. (NASDAQ: OPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OPRX stands at 149.2M. In comparison, CERN has a market cap of 0. Regarding current trading prices, OPRX is priced at $7.95 on the NASDAQ, while CERN trades at $94.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OPRX currently has a P/E ratio of 7.29, whereas CERN's P/E ratio is 55.84. In terms of profitability, OPRX's ROE is +0.04%, compared to CERN's ROE of +0.14%. Regarding short-term risk, OPRX is more volatile compared to CERN. This indicates higher risk in terms of short-term price fluctuations for OPRX.Check CERN's competition here